RxDoctor Payments Data

Jyldyz Temirkan

Family · Chandler, AZNPI 1497463715

Payments from drug & device makers

$1,967in general payments, 2019–2025

Across 75 payments — averaging $26.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$530
  • Amgen$438
  • Medtronic$163
  • Lilly USA, LLC$108
  • Abbott$107
  • Novo Nordisk$82
  • plus $538 from 18 others

What the payments were for

  • Food & beverage$1,95599%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,967 in reported general payments places this provider in the 80th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$14,350
Medicare patients
43
Services billed
223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide90$147,029
OzempicSemaglutide79$124,040
FarxigaDapagliflozin Propanediol79$93,491
JardianceEmpagliflozin51$70,940
RybelsusSemaglutide20$53,357
JanuviaSitagliptin Phosphate24$35,619
EliquisApixaban12$20,315
VascepaIcosapent Ethyl26$15,239
Icosapent Ethyl20$4,024
Atorvastatin Calcium451$3,921
LantusInsulin Glargine,hum.Rec.Anlog43$3,419
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,796
Gabapentin140$2,558
Omeprazole109$2,487
Metformin Hcl282$1,720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$82$177,39799 claims
Lilly USA, LLCTrulicity$108$147,02990 claims
AstraZenecaFarxiga$530$93,49179 claims
Boehringer IngelheimJardiance$30$70,94051 claims
MerckJanuvia$18$35,61924 claims
PfizerEliquis$70$20,31512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,119 family providers in Arizona.

Other family in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →